Medical Devices Startups
6,372 companies tagged Medical Devices, with their investors and founders.
TTP develops the Thermo Trauma Port, a novel patient transfer device for the trauma care pathway, created with a consortium including East Anglian Air Ambulance, University Hospital of Birmingham and the University of Portsmouth. The device targets pre-hospital and in-hospital emergency and critical care settings, with clinical usability testing conducted through the NIHR.
2 investors
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
2 investors
Tium Bio develops immunotherapy drugs for treating rare and intractable diseases. The company focuses on oncology indications including head and neck cancer, with a pipeline of differentiated candidates in clinical development.
2 investors
Tombot creates animatronic robotic pets designed to provide companionship and therapeutic benefits for people who cannot care for live animals, with initial focus on treating behavioral and psychological symptoms in older adults with dementia. The company aims to achieve FDA approval as a medical device while expanding to serve the broader market of 4 billion people globally who do not keep live animals as pets.
2 investors
Tomorrow's Bio Today develops the "SIGH CAM," a patent-pending imaging device intended as a less invasive, lower-cost alternative to traditional colonoscopy and endoscopy for use by large-animal veterinarians on livestock such as cattle, horses, and sheep. The company focuses on veterinary and animal health technology.
2 investors
Abbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
2 investors
Toro Bio develops automated systems for cell and gene therapy production at point of care, enabling personalized cancer therapies. The company focuses on streamlining process development and manufacturing for therapeutic applications.
2 investors
Torramics is developing an ultra-small disposable insulin patch pump ("nanoPump") that combines nanofluidic technology with a nanoCompressor to deliver three days of insulin in a compact form factor. The device targets people living with insulin-dependent diabetes.
2 investors
TORTUS develops health technology with a focus on clinical evidence and sustainable growth. The company prioritizes rigorous trials, scientific validation, and demonstrable value delivery to clinicians and patients over rapid, disruption-focused approaches.
2 investors
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need. The company translates scientific discoveries in immune regulation and regenerative medicine into novel patient therapies.
2 investors
Trace Biosciences develops technology to make nerves visible in real time during surgical procedures, enabling surgeons to better identify and preserve nerve structures. The company targets operating rooms with fluorescent imaging agents and related surgical visualization tools.
2 investors
Trace Orthopedics is developing a device and technique (the Trace Method) to repair partially torn tendons back to bone through a needle inserted through the skin, avoiding open or arthroscopic surgery and general anesthesia. The percutaneous tendon repair product is aimed at surgeons treating tendon injuries, in the medical device industry.
2 investors
TrakCel develops technology solutions for clinical trial services and cell therapy supply chain management, including cold chain logistics and software platforms for advanced therapy deployment. The company serves pharmaceutical companies and advanced therapy developers managing complex patient-centric operations globally.
2 investors
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures. Its products serve surgeons and hospitals in the operating room across international markets.
2 investors
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.
2 investors
Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.
2 investors
Trialbee is a clinical trial platform designed to accelerate the execution and delivery of clinical trials. The company serves biopharmaceutical and medical research organizations.
2 investors
Formation Bio develops drugs alongside research site partners, including health systems, academic medical centers, and independent research sites, with a focus on accelerating clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides technology solutions, monitoring services, and enrollment support to streamline the drug development process.
2 investors
Trimedx is a clinical asset performance company that manages medical devices across health systems using on-site technicians, proprietary datasets, and AI-driven intelligence to optimize device reliability, reduce costs, and enhance security. It serves integrated delivery networks, regional and academic health systems, and community healthcare providers.
2 investors
Trince is a Ghent University spin-off developing photoporation technology for physical transfection of cells as an alternative to viral vectors and electroporation. Its technology, including the Lumipore platform, targets R&D, manufacturing, and GMP-compliant clinical applications such as cell and gene therapy.
2 investors
Trioar is a platform company developing next-generation antibody-based technologies to improve the efficacy and therapeutic index of antibody-based therapeutics, including enhanced ADC (antibody-drug conjugate) options. The company focuses on immuno-oncology and cell-targeting therapies for patients with tumors.
2 investors
TriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
2 investors
Endologix develops endovascular medical devices for treating vascular conditions such as abdominal aortic aneurysms and peripheral arterial disease in the femoropopliteal arteries. Its stent grafts and revascularization systems are used by physicians performing minimally invasive vascular repair.
2 investors
Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations. The company focuses on oncology with applications in regenerative medicine, beginning with glioblastoma.
2 investors